BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia
The U.S. Food and Drug Administration accepted Biohaven’s resubmitted application for its experimental neurological disease drug, Vyglxia. The FDA issued a Complete Response Letter last November, declining to approve the drug. The FDA set a target deadline …